Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. During the same quarter in the prior year, the business posted ($1.78) earnings per share.

Read Our Latest Report on Sutro Biopharma Sutro Biopharma Price Performance Shares of NASDAQ STRO opened at $0.80 on Wednesday. Sutro Biopharma has a 1-year low of $0.76 and a 1-year high of $6.13 ...

Sutro Biopharma Inc (NASDAQ:STRO) has prioritized three wholly owned pre-clinical programs in its next-generation ADC pipeline, indicating a focused strategic direction. The company's cash runway ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody ...

Sutro Biopharma (NASDAQ:STRO) said on Thursday that, under its portfolio review, the company has decided to advance its dual-payload ADC programs, while deprioritizing development of luveltamab ...

"Thank you to all who have been on this journey with us and thank you to those continuing the Sutro journey as we part company," the outgoing CEO said. Sutro Biopharma CEO Bill Newell left the ...

Sutro Biopharma (NASDAQ:STRO) fell ~14% in the premarket on Friday after the company announced its decision to deprioritize its studies into the antibody-drug conjugate luveltamab tazevibulin as ...

Sutro Biopharma is cutting 65 jobs across two Bay Area locations. The layoffs, which are permanent according to state filings, will see three people lose their jobs at Sutro’s South San ...

Piper Sandler downgraded Sutro Biopharma (STRO) to Neutral from Overweight with a price target of $2, down from $8. The company is deprioritizing development of luvelta in order to focus resources ...

Sutro Biopharma’s 2024 revenue fell to $62 million from $153.7 million in 2023. The company expects its cash runway to last through at least Q4 2026, excluding potential milestone payments. Feel ...

Oppenheimer downgraded Sutro Biopharma (STRO) to Perform from Outperform. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses.